D. Olivera

Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass

R. Ritchie, N. Lane, S. Amugongo, 2014, Osteoporosis International.

Human osteoclastoma‐derived stromal cells: Correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo

I. James, M. Nuttall, R. Dodds, 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Induction of non-specific suppressor cells and myeloregulatory effects of an immunomodulatory azaspirane, SK&F 105685.

J. Talmadge, A. Badger, A. King, 1991, International journal of immunopharmacology.

Human Trabecular Bone Cells Are Able to Express Both Osteoblastic and Adipocytic Phenotype: Implications for Osteopenic Disorders

M. Nuttall, M. Gowen, A. Patton, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Beneficial effects of SK&F 105809, a novel cytokine-suppressive agent, in murine models of endotoxin shock.

J. Lee, A. Badger, K. Esser, 1992, Circulatory shock.

Protective effect of SK&F 86002, a novel dual inhibitor of arachidonic acid metabolism, in murine models of endotoxin shock: inhibition of tumor necrosis factor as a possible mechanism of action.

J. Talmadge, A. Badger, N. Hanna, 1989, Circulatory shock.

Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.

A. Badger, K. Esser, D. Olivera, 1994, Circulatory shock.

Beneficial effects of long-term treatment with SK&F 105685 in murine lupus nephritis.

A. Badger, B. Short, A. King, 1990, The Journal of pharmacology and experimental therapeutics.

Inhibition of lymphoproliferative responses by SK&F 105685, a novel anti-arthritic agent.

A. Badger, P. Bugelski, T. Newman-Tarr, 1991, Journal of clinical & laboratory immunology.